Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LeSoleil

            Therapeutic Area: Infections and Infectious Diseases Product Name: LeSoleil

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2021

            Details:

            LeSoleil' series of drugs can block the broad-spectrum coronavirus infection, resist further development of respiratory infection and kill the viruses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBV154

            Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2021

            Details:

            Bharat Biotech applied to the DCGI seeking permission for conducting phase 1 and phase 2 clinical trials for BBV154, following which the subject expert committee of the CDSCO deliberated on the application and recommended granting permission for phase 1 trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LeSoleil

            Therapeutic Area: Infections and Infectious Diseases Product Name: LeSoleil

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 24, 2020

            Details:

            LeSoleil', a naturally active compound, was discovered as a therapeutic candidate for use against COVID-19. Results from a study conducted by Suntrap Life Technologies indicated 'LeSoleil' has a potent in vitro inhibitory effect on COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBV152

            Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            COVAXINTM is developed using Whole-Virion Inactivated Vero Cell derived platform technology. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 high containment facility.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HGCO19

            Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: HDT Biotech

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            The Drugs Controller General of India (DCGI) has granted conditional permission for phases 1 and 2 human clinical trial of the COVID-19 vaccine candidate, HGCO19, developed by the Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, USA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Attenuated recombinant measles viruses

            Therapeutic Area: Infections and Infectious Diseases Product Name: rMeVs

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Biological E

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 08, 2020

            Details:

            OSIF has licensed novel live attenuated measles virus vectored vaccine candidates against SARS-CoV-2, which were developed by the Ohio State University College of Veterinary Medicine, exclusively to Biological E. Limited (BE).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CDX-005

            Therapeutic Area: Infections and Infectious Diseases Product Name: CDX-005

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Codagenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HGCO19

            Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 24, 2020

            Details:

            In collaboration with HDT Biotech Corporation, Seattle, USA, Gennova has developed an mRNA vaccine candidate (HGCO19), with demonstrated safety, immunogenicity, neutralization antibody activity in the rodent and non-human primate models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Covid-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            Panacea Biotec has set production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.